Technology
Health
Biotechnology

MediciNova

$11.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (2.68%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MediciNova and other stocks, options, ETFs, and crypto commission-free!

About

Medicinova Inc Common Stock, also called MediciNova, is a biopharmaceutical company. It is engaged in acquiring and developing novel, small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Read More The firm's development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Employees
9
Headquarters
La Jolla, California
Founded
2000
Market Cap
481.42M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
90.74K
High Today
$11.63
Low Today
$11.27
Open Price
$11.63
Volume
25.46K
52 Week High
$13.37
52 Week Low
$6.68

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
Pharmaceutical
US

News

Yahoo FinanceMay 8

If You Had Bought MediciNova (NASDAQ:MNOV) Stock Five Years Ago, You Could Pocket A 536% Gain Today

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly amazing gains over the years. Just think about the savvy investors who held MediciNova, Inc. (NASDAQ:MNOV) shares for the last five years, while they gained 536%. If that doesn't get you thinking about long term investing, we don't know what will. On top of that, the sha...

1,045
Markets InsiderMay 8

MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom

135

Earnings

-$0.16
-$0.11
-$0.06
-$0.01
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.12 per share
Actual
Expected May 28, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.